Home / Resource Library / A PHASE 1 STUDY OF KITE-363 ANTI-CD19/CD20 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA
A PHASE 1 STUDY OF KITE-363 ANTI-CD19/CD20 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA